問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Surgery

Division of Hematology & Oncology

更新時間：2023-09-19

羅竹君Loh, Zhu-Jun
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

Recruiting Trial

64Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

羅竹君

List

74Cases

2025-12-08 - 2032-09-03

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-10-15 - 2027-09-01

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Recruiting13Sites

2017-02-01 - 2027-02-01

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-04-25 - 2029-02-28

Phase I/II

Active
An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors

  • Condition/Disease

    Advanced HR+/HER2- Breast Cancer、 Advanced CCNE1-amplified Solid Tumors

  • Test Drug

    膠囊劑

Participate Sites
1Sites

Recruiting1Sites

2023-03-11 - 2027-03-01

Phase III

Active
Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor Therapy

  • Condition/Disease

    Breast Cancer

  • Test Drug

    注射劑

Participate Sites
8Sites

Recruiting8Sites

2025-06-30 - 2028-12-31

Phase I

Not yet recruiting
A Phase 1, Multicenter Trial of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

  • Condition/Disease

    Recurrent or Metastatic Solid Tumors

  • Test Drug

    Frozen crystal powder and liquid for injection

Participate Sites
5Sites

Recruiting5Sites

2025-06-01 - 2028-05-31

Phase III

Not yet recruiting
A Phase 3, Randomized, Multicenter, Parallel-arm, Double-blind Study to Compare Efficacy and Safety of EG1206A (EirGenix’ Pertuzumab) and Perjeta® (Pertuzumab) Sourced from EU as Neoadjuvant Treatment in Combination with Trastuzumab and Chemotherapy in Patients with HER2-positive Hormone Receptor-negative Early Breast Cancer

  • Condition/Disease

    HER2-positive Hormone Receptor-negative Early Breast Cancer

  • Test Drug

    injection

Participate Sites
11Sites

Recruiting11Sites

2023-04-01 - 2030-12-31

Phase III

Active
A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Who Progressed During or After CDK4/6 Inhibitor and Endocrine Combination Therapy

  • Condition/Disease

    Breast Cancer

  • Test Drug

    GDC-0077(Inavolisib)Alpelisib(Piqray)Fulvestrant (Faslodex)

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2021-06-01 - 2031-12-24

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting2Sites

Recruiting4Sites

2021-02-08 - 2023-07-20

Phase III

A randomized, multicenter, double-blind phase 3 study of SAR439859 plus palbociclib versus letrozole plus palbociclib for the treatment of patients with ER (+), HER2 (-) breast cancer who have not received prior systemic anti-cancer treatment for advanced disease

  • Condition/Disease

    ER (+), HER2 (-) breast cancer

  • Test Drug

    SAR439859

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting6Sites

1 4 5 6 7 8
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB